Men with severe hemophilia in the United States: Birth cohort analysis of a large national database

Blood

Volumn 127, Issue 24, 2016, Pages 3073-3081

  Mazepa, Marshall A ^a   Monahan, Paul E ^a   Baker, Judith R ^b,c   Riske, Brenda K ^d   Soucie, J Michael ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Center for Inherited Blood Disorders   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ABSENTEEISM; ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISABILITY; DISEASE SEVERITY; DISEASE SURVEILLANCE; EMPLOYMENT; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; SURVIVAL; COMPLICATION; FACTUAL DATABASE; HEALTH CARE DELIVERY; INFANT; MIDDLE AGED; NEWBORN; NEWBORN SCREENING; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; CHILD, PRESCHOOL; COHORT STUDIES; DATABASES, FACTUAL; HEALTH SERVICES ACCESSIBILITY; HEMOPHILIA A; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEONATAL SCREENING; SEVERITY OF ILLNESS INDEX; SEX FACTORS; UNITED STATES;

EID: 84975796441     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-10-675140     Document Type: Article

References (34)

1. Evatt BL. The natural evolution of haemophilia care: developing and sustaining comprehensive care globally. Haemophilia. 2006;12(Suppl 3): 13-21.
2. Evatt BL. The tragic history of AIDS in the hemophilia population, 1982-1984. J Thromb Haemost. 2006;4(11):2295-2301.
3. Public Law 9463: The Public Health Service Act Establishing the Hemophilia Diagnostic and Treatment Center Program. N01131 of Public Law 9463. Washington, DC: Government Printing Office; 1975.
4. Baker JR, Crudder SO, Riske B, Bias V, Forsberg A. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health. 2005;95(11):1910-1916.
5. Soucie JM, McAlister S, McClellan A, Oakley M, Su Y. The universal data collection surveillance system for rare bleeding disorders. Am J Prev Med. 2010;38(4 Suppl):S475-S481.
6. Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407-412.
7. Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014; 12(11):1935-1939.
8. Humes K, Jones N, Ramirez R. Overview of race and Hispanic origin: 2010. US Census Bureau. Washington, DC: Government Printing Office; 2011:1-24.
9. Smedley BD. Moving beyond access: achieving equity in state health care reform. Health Aff (Millwood). 2008;27(2):447-455.
10. DeNavas-Walt C, Proctor BD, Smith JC. Income, poverty and health insurance coverage in the United States: 2009. US Census Bureau. Washington, DC: Government Printing Office; 2010:60-238.
11. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998;4(1):68.
12. Goudemand J, Rothschild C, Demiguel V, et al; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107(1):46-51.
13. Miller CH, Benson J, Ellingsen D, et al; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012; 18(3):375-382.
14. Carpenter SL, Michael Soucie J, Sterner S, Presley R; Hemophilia Treatment Center Network (HTCN) Investigators. Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia. 2012;18(3): e260-e265.
15. Walsh CE, Soucie JM, Miller CH; United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol. 2015;90(5):400-405.
16. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology. 2000;31(4):1014-1018.
17. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995;332(22):1463-1466.
18. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol. 1999; 31(Suppl 1):17-24.
19. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-472.
20. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20(6):1527-1536.
21. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-232.
22. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370(3):211-221.
23. Liang TJ, Ghany MG. Therapy of hepatitis C-back to the future. N Engl J Med. 2014;370(21): 2043-2047.
24. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3): 932-954.
25. Medical and Scientific Advisory Council of the National Hemophilia Foundation: MASAC Recommendations on Treatment of Hepatitis C in Individuals with Hemophilia and Other Bleeding Disorders. New York, NY: Medical and Scientific Advisory Council; 2015.
26. Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia. 2013; 19(1):21-26.
27. Gupta S, Siddiqi AE, Soucie JM, et al; Joint Outcomes Committee of Universal Data Collection and the Hemophilia Treatment Centres Network. The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. Br J Haematol. 2013;161(3):424-433.
28. Petit C, Klein H. Hemophilia, Hemophiliacs and the Health Care Delivery System. Washington, DC: National Heart and Lung Institute, Division of Blood Disease and Resources, Office of Prevention, Control, and Education; 1976:76-871.
29. Rabiner SF, Telfer MC. Home transfusion for patients with hemophilia A. N Engl J Med. 1970; 283(19):1011-1015.
30. Levine PH. Efficacy of self-therapy in hemophilia. A study of 72 patients with hemophilia A and B. N Engl J Med. 1974;291(26):1381-1384.
31. Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics. 1973;51(6):986-991.
32. Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia. 2004;10(2):118-133.
33. Baker JR, Riske B, Voutsis M, Cutter S, Presley R. Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia. Am J Prev Med. 2011;41(6 Suppl 4):S338-S345.
34. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-the evidence report. Obes Res. 1998;6(Suppl 2):51S-209S.